Cargando…
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch
US Food and Drug Administration (FDA)‐approved diagnostic assays play an increasingly common role in managing patients to prolong lifespan while also enhancing quality of life. Diagnostic assays can be essential for the safe and effective use of therapeutics (companion diagnostic), or may inform on...
Autores principales: | Scheerens, H, Malong, A, Bassett, K, Boyd, Z, Gupta, V, Harris, J, Mesick, C, Simnett, S, Stevens, H, Gilbert, H, Risser, P, Kalamegham, R, Jordan, J, Engel, J, Chen, S, Essioux, L, Williams, JA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355969/ https://www.ncbi.nlm.nih.gov/pubmed/28121072 http://dx.doi.org/10.1111/cts.12455 |
Ejemplares similares
-
Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas
por: Ward, Derek J, et al.
Publicado: (2019) -
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
por: Plönes, Till, et al.
Publicado: (2016) -
Ethical and Practical Considerations Associated with Companion Animal Euthanasia
por: Cooney, Kathleen, et al.
Publicado: (2023) -
Strategic and Statistical Considerations on the QT Assessment of Volasertib
por: Wallenstein, Gudrun, et al.
Publicado: (2017) -
Announcing the launching of Toxicology Reports
por: Lash, Lawrence H.
Publicado: (2014)